Lixia Wu

Zhonghuaxin Road 619
Shanghai, 200040, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 22 publications

Detection and clinical significance of peripheral blood myeloid-derived suppressor cells in patients with multiple myeloma.

Detection and clinical significance of peripheral blood myeloid-derived suppressor cells in patients with multiple myeloma.

Journal: Medicine

Published: July 22, 2025

Impact of immunochemotherapy administration sequence on overall survival in advanced esophageal and gastric cancers: a propensity score-matched multicenter analysis.

Impact of immunochemotherapy administration sequence on overall survival in advanced esophageal and gastric cancers: a propensity score-matched multicenter analysis.

Journal: Cancer immunology, immunotherapy : CII

Published: June 19, 2025

Piwi-interacting RNA-823 promotes cell growth and chemoresistance by stimulating the TGF-β1-mediated AKT/ERK pathway in multiple myeloma.

Piwi-interacting RNA-823 promotes cell growth and chemoresistance by stimulating the TGF-β1-mediated AKT/ERK pathway in multiple myeloma.

Journal: International immunopharmacology

Published: March 31, 2025

Thrombotic events in patients with multiple myeloma and their impact on overall survival.

Thrombotic events in patients with multiple myeloma and their impact on overall survival.

Journal: Hematology (Amsterdam, Netherlands)

Published: February 19, 2025

Clinicopathologic predictors of renal response and survival in newly diagnosed multiple myeloma with renal injury: a retrospective study.

Clinicopathologic predictors of renal response and survival in newly diagnosed multiple myeloma with renal injury: a retrospective study.

Journal: Clinical and experimental medicine

Published: November 07, 2024

PPP3CB inhibits pancreatic cancer progression by promoting ATOH8 translocation and transcriptionally regulating Sp1.

PPP3CB inhibits pancreatic cancer progression by promoting ATOH8 translocation and transcriptionally regulating Sp1.

Journal: Life sciences

Published: October 10, 2024

Pan-cancer analysis of Sp1 with a focus on immunomodulatory roles in gastric cancer.

Pan-cancer analysis of Sp1 with a focus on immunomodulatory roles in gastric cancer.

Journal: Cancer cell international

Published: June 23, 2024

Association of the CD4+/CD8+ ratio with response to PD-1 inhibitor-based combination therapy and dermatological toxicities in patients with advanced gastric and esophageal cancer.

Association of the CD4+/CD8+ ratio with response to PD-1 inhibitor-based combination therapy and dermatological toxicities in patients with advanced gastric and esophageal cancer.

Journal: International immunopharmacology

Published: May 22, 2023

Continuous low-dose cyclophosphamide plus prednisone in the treatment of relapsed and refractory multiple myeloma with severe complications.

Continuous low-dose cyclophosphamide plus prednisone in the treatment of relapsed and refractory multiple myeloma with severe complications.

Journal: Frontiers in oncology

Published: March 14, 2023

Presentation and outcomes of patients with multiple myeloma harboring gain or amplification of 1q21 and receiving novel agent therapies: results from a single-center study.

Presentation and outcomes of patients with multiple myeloma harboring gain or amplification of 1q21 and receiving novel agent therapies: results from a single-center study.

Journal: Hematology (Amsterdam, Netherlands)

Published: February 16, 2023

Evaluation of the Mayo Additive Staging System in patients with newly diagnosed multiple myeloma: A real-world analysis.

Evaluation of the Mayo Additive Staging System in patients with newly diagnosed multiple myeloma: A real-world analysis.

Journal: European journal of haematology

Published: September 22, 2022

The applicability of the Second Revision of the International Staging System for patients with multiple myeloma receiving immunomodulatory drugs or proteasome inhibitor-based regimens as induction treatment: A real-world analysis.

The applicability of the Second Revision of the International Staging System for patients with multiple myeloma receiving immunomodulatory drugs or proteasome inhibitor-based regimens as induction treatment: A real-world analysis.

Journal: Hematological oncology

Published: June 09, 2022

Showing 1-12 of 22

Last Updated: 09/26/2026